Drug Search Results
Using advanced filters...
Advanced Search [+]

AZD-5213

Alternative Names: azd-5213, azd5213, azd 5213
Clinical Status: Inactive
Latest Update: 2017-02-07
Latest Update Note: Clinical Trial Update

Product Description

AZD5213 is potent, competitive, rapidly reversible, functional antagonist (inverse agonist) at the human H3 receptor. (Sourced from: https://openinnovation.astrazeneca.com/clinical-research/clinical-molecules/azd5213.html)

Mechanisms of Action: H3 Inverse Agonist

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: AstraZeneca
Company Location: CAMBRIDGE X0 CB2 0AA
Company CEO: Pascal Soriot
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Recent & Upcoming Milestones

Highest Development Phases

Phase 2: Alzheimer Disease|Cognitive Dysfunction|Rett Syndrome|Tourette Syndrome|Low Back Pain

Phase 1: Healthy Volunteers

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

D3031C00001

P2

Completed

Low Back Pain

2015-05-01

2024-06-26

Primary Endpoints|Treatments

D3032C00001

P2

Completed

Tourette Syndrome|Rett Syndrome

2015-02-01

2019-03-19

Treatments

D3030C00005

P2

Completed

Cognitive Dysfunction|Alzheimer Disease

2013-01-01

2019-03-19

Treatments

D3030C00004

P1

Completed

Healthy Volunteers

2011-10-01

2019-03-19

Treatments

D3030C00002

P1

Completed

Healthy Volunteers

2011-05-01

2019-03-19

Treatments

D3030C00003

P1

Completed

Healthy Volunteers

2011-06-01

2019-03-19

Treatments

D3030C00001

P1

Completed

Healthy Volunteers

2010-12-01

2019-03-19

Treatments

Recent News Events

Date

Type

Title